Dianthus price target raised to $110 from $63 at Truist

Truist raised the firm’s price target on Dianthus (DNTH) to $110 from $63 and keeps a Buy rating on the shares. The firm is citing the company having announced an early “Go” decision for claseprubart in its CIDP program based on open-label Part A data that exceeded the about 50% response-rate threshold for advancement into the pivotal portion of the CAPTIVATE trial. The original bar was a 40%-50% response rate with 16-20 responders among the first 40 patients, and the results appear stronger than those reported by Sanofi’s (SNY) C1s inhibitor, riliprubart, in its open-label Phase 2 CIDP study, the analyst tells investors in a research note.